血管移植物与腔内移植物感染的治疗与随访:Delphi共识文件
该改良Delphi共识通过4轮调查、5点Likert量表、≥75%同意为共识标准,由感染病、血管与心胸外科、微生物学和核医学专家参与,针对血管移植物或腔内移植物感染(VGEI)的抗微生物治疗、外科管理和随访形成10条一般声明和35条具体声明。共识强调经验性抗菌仅用于出现脓毒症、出血等并发症或诊断干预延迟的患者,并根据移植物位置和危险因素个体化。无主动脉肠瘘的腹主动脉VGEI病原未知时初始覆盖革兰阳性球菌、革兰阴性杆菌和厌氧菌,按风险考虑MRSA/MRSE;无瘘的胸部VGEI优先覆盖革兰阳性菌,可选MRSA覆盖。完全移除移植物并自体静脉替换者推荐6周抗生素疗程,有生物利用度好的口服选项可早期转口服;残留人工材料者建议至少4–6周静脉治疗后口服,总疗程12周。毒力强病原、感染源控制不完全或炎症标志物持续升高者应考虑延长治疗。
要点
- 仅出现脓毒症、出血等并发症或诊断干预延迟时才启动经验性抗菌治疗,且需根据移植物位置和危险因素个体化。
- 无主动脉肠瘘的腹主动脉VGEI病原未知时,初始覆盖革兰阳性球菌、革兰阴性杆菌和厌氧菌,按风险考虑MRSA/MRSE覆盖。
- 无瘘的胸部VGEI优先覆盖革兰阳性菌,MRSA覆盖为可选。
- 完全移除移植物并自体静脉替换者推荐6周抗生素疗程,有生物利用度好的口服选项可早期转口服。
- 残留人工材料者建议至少4–6周静脉治疗后口服,总疗程12周;毒力强病原、感染源控制不完全或炎症标志物持续升高者考虑延长治疗。
适用人群与场景
- 血管移植物或腔内移植物感染(VGEI)患者,涵盖腹部和胸部VGEI,包括无主动脉肠瘘和无瘘的情况。
诊断标准与关键阈值
- 共识判定标准:5点Likert量表评分中≥75%同意(同意/强烈同意)视为达成共识;轮次间内部一致性用Cronbach's alpha评估,>0.80。
处置流程与药物剂量
- 经验性抗菌治疗仅用于出现并发症(如脓毒症和出血)或诊断干预延迟的患者,并须根据移植物位置和危险因素个体化。
- 无主动脉肠瘘且病原未知的腹主动脉VGEI:初始覆盖革兰阳性球菌、革兰阴性杆菌和厌氧菌,按风险考虑MRSA/MRSE覆盖。
- 无瘘的胸部VGEI:优先覆盖革兰阳性菌,可选MRSA覆盖。
- 完全移除移植物并自体静脉替换者:推荐6周抗生素疗程,有生物利用度好的口服选项时可早期转口服。
- 残留人工材料者:建议至少4–6周静脉治疗后口服治疗,总疗程12周。
- 毒力强病原、感染源控制不完全或炎症标志物持续升高者:考虑延长治疗。
红旗征与不能漏的情况
- 出现脓毒症或出血等并发症时需启动经验性抗菌治疗。
- 诊断干预延迟时需启动经验性抗菌治疗。
研究设计与关键结果
- 采用改良Delphi法,4轮调查,专家小组来自感染病、血管与心胸外科、微生物学和核医学,对10条一般声明和35条具体声明进行5点Likert量表评分。
- 共识达成标准为≥75%同意(同意/强烈同意),轮次间内部一致性用Cronbach's alpha评估(>0.80)。
证据类型、等级与局限
- 证据类型:Delphi专家共识。
- 共识达成标准:≥75%同意;内部一致性Cronbach's alpha>0.80。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对无并发症且诊断干预未延迟的VGEI患者,不启动经验性抗菌治疗,等待微生物学结果以指导治疗。
- 腹主动脉VGEI病原未知且无主动脉肠瘘时,经验性方案需同时覆盖革兰阳性球菌、革兰阴性杆菌和厌氧菌,并按风险考虑MRSA/MRSE。
- 胸部VGEI无瘘时,经验性方案优先覆盖革兰阳性菌,MRSA覆盖为可选。
- 完全移除移植物并自体静脉替换者,6周抗生素疗程即可,有生物利用度好的口服选项可早期转口服。
- 残留人工材料者需至少4–6周静脉治疗后续口服,总疗程12周;毒力强病原、感染源控制不完全或炎症标志物持续升高者考虑延长。
指南或共识出处
- Delphi共识文件:Treatment and follow-up of vascular graft and endograft infection: Delphi consensus document(Clin Microbiol Infect)。
提炼说明
- 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
SCOPE: Vascular graft or endograft infection (VGEI) is a severe complication requiring a multidisciplinary approach combining surgery and antimicrobial therapy. This study aimed to develop expert consensus on the management and follow-up of VGEI, with a focus on antimicrobial strategies.
METHODS: A modified Delphi method was conducted to reach consensus on key aspects of VGEI care, including antimicrobial treatment, surgical management, and follow-up. An expert panel representing infectious diseases, vascular and cardiothoracic surgery, microbiology, and nuclear medicine participated in four rounds of surveys. Ten general and 35 specific statements were rated using a five-point Likert scale. Statements with ≥75% agreement (agree/strongly agree) were considered to have achieved consensus. Internal consistency across rounds was assessed using Cronbach's alpha (>0.80).
QUESTIONS ADDRESSED BY THE DELPHI METHOD AND RECOMMENDATIONS: The panel agreed that empirical antimicrobial therapy should be initiated only in patients with complications (e.g. sepsis and bleeding) or when diagnostic intervention is delayed. Empirical therapy must be individualized based on graft location and risk factors. For abdominal VGEI without aorto-enteric fistula and unknown pathogens, initial coverage should target gram-positive cocci, gram-negative bacilli, and anaerobes, with consideration for Methicillin-Resistant Staphylococcus aureus (MRSA)/Methicillin-Resistant Staphylococcus epidermidis (MRSE) based on risk. For thoracic VGEI without fistula, gram-positive coverage is prioritized, with optional MRSA coverage. Postoperative treatment duration should be individualized. In cases of complete graft removal and replacement with autologous veins, a 6-week antibiotic course is recommended, with early oral switch if bioavailable options are available. If prosthetic material remains, at least 4 to 6 weeks of intravenous therapy followed by oral treatment for a total of 12 weeks is advised. Prolonged therapy should be considered in cases with virulent pathogens, incomplete source control, or persistent inflammatory markers. The study provides practical, expert-based antimicrobial guidance for VGEI management and emphasizes the importance of individualized, microbiologically informed therapy within a multidisciplinary care framework.
参考来源
- Kouijzer IJE, Hernández-Meneses M, Aarntzen EHJG, et al. Treatment and follow-up of vascular graft and endograft infection: Delphi consensus document. Clin Microbiol Infect. 2025. PMID: 40744275. doi:10.1016/j.cmi.2025.07.020
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。